Citadel Advisors’s Monte Rosa Therapeutics GLUE Stock Holding History

Citadel Advisors’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$541K	Buy	32,900 +13,400	+69%	+$256K	﹤0.01%	9104
2025 Q4	$306K	Sell	19,500 -9,000	-32%	-$121K	﹤0.01%	10098
2025 Q3	$211K	Buy	+28,500	New	+$151K	﹤0.01%	11156
2025 Q2	–	Sell	-22,400	Closed	-$104K	–	13457
2025 Q1	$104K	Buy	22,400 +6,500	+41%	+$39.9K	﹤0.01%	11403
2024 Q4	$110K	Sell	15,900 -15,300	-49%	-$115K	﹤0.01%	11335
2024 Q3	$165K	Buy	31,200 +22,700	+267%	+$115K	﹤0.01%	10428
2024 Q2	$31.8K	Buy	8,500 +7,300	+608%	+$37.2K	﹤0.01%	12209
2024 Q1	$8.46K	Sell	1,200 -9,800	-89%	-$58.1K	﹤0.01%	13551
2023 Q4	$62.1K	Buy	+11,000	New	+$43.2K	﹤0.01%	11548
2023 Q1	–	Sell	-1,400	Closed	-$10.7K	–	14997
2022 Q4	$10.7K	Buy	+1,400	New	+$11.7K	﹤0.01%	13608

Other funds holding GLUE

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Citadel Advisors's GLUE Position: Q1 2026 in Review

Citadel Advisors increased its Monte Rosa Therapeutics (GLUE) stake by 450% in Q1 2026, buying an estimated $3.98M and bringing the position to 254,518 shares worth $4.19M. The position accounts for ﹤0.01% of the portfolio, ranked #4639.

Citadel Advisors first reported a position in GLUE in Q2 2021 and has held it in 19 quarters since. The position peaked at $7.79M in Q3 2022. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

Citadel Advisors held 254,518 shares of Monte Rosa Therapeutics worth $4.19M as of Q1 2026.
Citadel Advisors bought 208,255 Monte Rosa Therapeutics shares in Q1 2026, an estimated $3.98M.
Monte Rosa Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4639 holding.
Citadel Advisors first reported a position in Monte Rosa Therapeutics in Q2 2021 and has held it in 19 quarters since.
Citadel Advisors's Monte Rosa Therapeutics position peaked at $7.79M in Q3 2022.
190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.